Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Co. (NYSE:LLY) has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
礼来（纽交所: LLY）已任命卢卡斯·蒙塔塞为执行副总裁兼首席财务官，即日起生效。
What Happened: Montarce, who joined Lilly in 2001, has held numerous finance leadership positions. His roles included group vice president, corporate controller, and CFO of Lilly Research Laboratories; vice president, finance and CFO of Lilly International; and vice president, finance, and global CFO of Elanco Health.
发生了什么: Montarce于2001年加入了礼来, 担任过多个金融领导职务。他的职责包括礼来研究实验室的集团副总裁、公司控制器和致富金融(临时代码);礼来国际的副总裁、财务和致富金融(临时代码);以及Elanco Health的副总裁、财务和全球致富金融(临时代码)。
Most recently, Montarce served as Lilly's president and general manager for the Spain, Portugal, and Greece hub. He holds a bachelor's degree in business accounting from Catholic University (Argentina) and a master's degree in business administration from the Center for Macroeconomic Studies of Argentina.
最近，蒙塔塞担任了礼来西班牙、葡萄牙和希腊地区的总经理。他拥有阿根廷天主教大学的工商会计学士学位，以及阿根廷宏观经济研究中心的工商管理硕士学位。
David Ricks, chair and CEO stated, "We are excited to announce Lucas as Lilly's next CFO, following a competitive search across health care, tech, and general industries."
董事长兼CEO大卫·瑞克斯表示：“我们很高兴宣布卢卡斯将成为礼来的下任首席财务官，经过医疗保健、科技和一般行业的竞争性搜索后。”
Montarce expressed his commitment to building on Lilly's strong financial foundation and driving continued success. "I am honored to step into this role during such a significant time in our company's history," he said.
蒙塔塞表示他致力于发展礼来强大的财务基础，推动持续成功。“在我们公司历史上这样重要的时刻接任这一职务，我感到非常荣幸，”他说。
Why It Matters: The appointment of Montarce as CFO comes at a pivotal time for Eli Lilly. The company has been in the spotlight for its advancements in the weight loss and GLP-1 space. Roundhill Investments CEO Dave Mazza recently likened Eli Lilly to NVIDIA Corp (NASDAQ:NVDA) in terms of market leadership and growth potential.
为什么重要：任命蒙塔塞为首席财务官正值礼来关键时刻。该公司因在减肥和GLP-1领域的进展而备受关注。Roundhill Investments首席执行官戴夫·马扎最近将礼来与NVIDIA Corp（纳斯达克: NVDA）相提并论，称其在市场领导地位和增长潜力方面类似。
Additionally, Eli Lilly's Alzheimer's drug, donanemab, is facing potential rejection by the U.K.'s National Health Service (NHS) due to cost and safety concerns, following a similar decision on Biogen Inc's (NASDAQ:BIIB) Leqembi. This has added pressure on the company to navigate regulatory challenges effectively.
此外，礼来的阿尔茨海默病药物多那�美正面临着英国国家医疗服务体系（NHS）可能因成本和安全问题而拒绝的风险，此前类似决定也发生在Biogen Inc（纳斯达克: BIIB）的Leqembi上。这给该公司增加了有效应对监管挑战的压力。
Montarce's appointment also follows the resignation of former CFO Anat Ashkenazi, who left to pursue a new career. Gordon Brooks has been serving as interim CFO since Jul. 15.
蒙塔塞的任命还是在前首席财务官阿纳特·阿什克纳兹辞职后进行的，她离职去追求新的职业道路。戈登·布鲁克斯自7月15日起一直担任临时CFO。
Moreover, Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. This move is part of a broader strategy to maintain its market position amid ongoing FDA debates about drug shortages.
此外，礼来正在加大力度打击其知名的压抑食欲药物Mounjaro和Zepbound的仿制品。这一举措是为了在持续进行FDA关于药物短缺的讨论的背景下保持其市场地位的更广泛策略的一部分。
Price Action: Eli Lilly and Co closed at $908.27 on Monday, gaining 0.62% for the day. In after-hours trading, the stock dipped 0.027%. Year to date, Eli Lilly's stock has surged 53.37%, according to data from Benzing Pro.
股价走势：礼来周一收盘价为908.27美元，当日上涨0.62%。盘后交易中，股价下跌0.027%。据Benzing Pro的数据，截至目前，礼来的股价已经上涨了53.37%。
